J. Scott Wolchko - Jul 22, 2021 Form 4 Insider Report for FATE THERAPEUTICS INC (FATE)

Role
President and CEO, Director
Signature
/s/ Cindy Tahl, Attorney-in-Fact
Stock symbol
FATE
Transactions as of
Jul 22, 2021
Transactions value $
-$4,934,113
Form type
4
Date filed
7/26/2021, 04:05 PM
Previous filing
May 24, 2021
Next filing
Aug 20, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction FATE Common Stock Options Exercise $81.9K +30K +7.62% $2.73 424K Jul 22, 2021 Direct F1
transaction FATE Common Stock Sale -$566K -6.63K -1.56% $85.38* 417K Jul 22, 2021 Direct F1, F2
transaction FATE Common Stock Sale -$1.88M -21.8K -5.22% $86.19* 395K Jul 22, 2021 Direct F1, F3
transaction FATE Common Stock Sale -$139K -1.6K -0.4% $86.90* 394K Jul 22, 2021 Direct F1, F4
transaction FATE Common Stock Options Exercise $27.3K +10K +2.54% $2.73 404K Jul 23, 2021 Direct F1
transaction FATE Common Stock Options Exercise $96.8K +20K +4.95% $4.84 424K Jul 23, 2021 Direct F1
transaction FATE Common Stock Sale -$2.56M -30K -7.08% $85.28* 394K Jul 23, 2021 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction FATE Stock Option (Right to Buy) Options Exercise $0 -30K -23.08% $0.00 100K Jul 22, 2021 Common Stock 30K $2.73 Direct F1, F5
transaction FATE Stock Option (Right to Buy) Options Exercise $0 -10K -10% $0.00 90K Jul 23, 2021 Common Stock 10K $2.73 Direct F1, F5
transaction FATE Stock Option (Right to Buy) Options Exercise $0 -20K -44.6% $0.00 24.8K Jul 23, 2021 Common Stock 20K $4.84 Direct F1, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 10, 2020.
F2 Represents the weighted average sale price of the shares sold ranging from $84.76 to $85.74 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each price.
F3 Represents the weighted average sale price of the shares sold ranging from $85.76 to $86.75 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each price.
F4 Represents the weighted average sale price of the shares sold ranging from $86.76 to $87.15 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each price.
F5 This option is fully vested.